Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node–Positive, Steroid Hormone Receptor–Positive Breast Cancer: Results From INT 0101 (E5188)
J Clin Oncol Davidson et al.
23: 5973
Publisher's Note
The September 1, 2005, article by Davidson et al titled, “Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node–Positive, Steroid Hormone Receptor–Positive Breast Cancer: Results From INT 0101 (E5188)” (J Clin Oncol 23:5973–5982, 2005) was published online on August 8, 2005, with incorrect information.
In the author affiliations section, the location of the Breast Center at Baylor College of Medicine/Methodist Hospital was given as Austin, TX, whereas it should have read Houston, TX. Also, the location of the John Wayne Cancer Institute was omitted; it should have read Santa Monica, CA.
In the third-to-last paragraph of the Discussion, in the third-to-last sentence, beginning “This trial had relaxed entry criteria”, the percentage of patients with ER-positive tumors was given as 76%, whereas it should have read 63% had receptor-positive tumors.
In the last paragraph of the Discussion, the definition of the acronym TEXT was given as Tamoxifen Oral Exemestane Trial. It should have read Tamoxifen and Exemestane Trial.
These corrections have been made as of August 15, 2005.
|
